The same drug might act differently in different patient populations. A bio-equivalent, generic or bio-similar drug might act differently in different populations also.
Anybody wonder what data FDA has on comparative safety and effectiveness of V and gV in Marine and Reduce-It populations?
A product we call gV is not yet on the market commercially, as far as I know.
News 
Market Data 
Discover 
